Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review

Amy L. Gillespie*, Ruta Samanaite, Jonathan Mill, Alice Egerton, James H. MacCabe

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

162 Citations (Scopus)
264 Downloads (Pure)

Abstract

Background: Schizophrenia is a highly heterogeneous disorder, and around a third of patients are treatment-resistant. The only evidence-based treatment for these patients is clozapine, an atypical antipsychotic with relatively weak dopamine antagonism. It is plausible that varying degrees of response to antipsychotics reflect categorically distinct illness subtypes, which would have significant implications for research and clinical practice. If these subtypes could be distinguished at illness onset, this could represent a first step towards personalised medicine in psychiatry. This systematic review investigates whether current evidence supports conceptualising treatment-resistant and treatment-responsive schizophrenoa as categorically distinct subtypes. Method: A systematic literature search was conducted, using PubMed, EMBASE, PsycInfo, CINAHL and OpenGrey databases, to identify all studies which compared treatment-resistant schizophrenia (defined as either a lack of response to two antipsychotic trials or clozapine prescription) to treatment-responsive schizophrenia (defined as known response to non-clozapine antipsychotics). Results: Nineteen studies of moderate quality met inclusion criteria. The most robust findings indicate that treatment-resistant patients show glutamatergic abnormalities, a lack of dopaminergic abnormalities, and significant decreases in grey matter compared to treatment-responsive patients. Treatment-resistant patients were also reported to have higher familial loading; however, no individual gene-association study reported their findings surviving correction for multiple comparisons. Conclusions: Tentative evidence supports conceptualising treatment-resistant schizophrenia as a categorically different illness subtype to treatment-responsive schizophrenia. However, research is limited and confirmation will require replication and rigorously controlled studies with large sample sizes and prospective study designs.

Original languageEnglish
Article number12
Pages (from-to)1-14
JournalBMC Psychiatry
Volume17
Issue number1
Early online date13 Jan 2017
DOIs
Publication statusPublished - 2017

Keywords

  • Classification
  • Clozapine
  • Schizophrenia
  • Treatment refractory
  • Treatment resistance
  • Treatment response

Fingerprint

Dive into the research topics of 'Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review'. Together they form a unique fingerprint.

Cite this